European Neuropsychopharmacology

Historical perspectives and current problems in the classification, diagnosis and treatment of mood disorders: New clinical specifiers
pp. S1/1-S1/1(1)
Author: Angst J.

Actions of drugs used against mood disorders on second messenger systems: A focus on the cAMP signaling system
pp. S1/1-S1/2(1)
Authors: Mork A.; Jensen J.B.

Critical progress in MAO inhibition in the treatment of mood disorders
pp. S1/3-S1/3(1)
Author: Vetulani J.

Neuropeptides: targets for antidepressants?
pp. S1/3-S1/4(1)
Author: van Ree J.M.

CRH in affective disorders
pp. S1/4-S1/4(1)
Author: Holsboer-Trachsler E.

Psychoimmunological aspects of mood disorders
pp. S1/6-S1/6(1)
Authors: Ackenheil M.; Muller N.

Acute and long term treatment - How long do you need to treat depression?
pp. S1/6-S1/7(1)
Author: Montgomery S.A.

Clinical Efficacy of Antidepressants in Unipolar Depression
pp. S1/7-S1/8(1)
Author: Paykel E.S.

New strategies in the management of refractory depression
pp. S1/8-S1/9(1)
Author: Dinan T.G.

Atypical and subclinical forms of bipolarity
pp. S1/9-S1/9(1)
Author: Cassano G.B.

Predictors of course and treatment response in bipolar affective disorder
pp. S1/9-S1/9(1)
Author: Scott J.

Depression, antidepressant drug treatment and cognitive impairment in old age
pp. S1/9-S1/10(1)
Author: Gottfries C.G.

Comparison of the clinical and pharmacological efficacy of the presently available drugs for mood disorders
pp. S1/10-S1/10(1)
Author: Leonard B.

Behavioural and in vivo microdialysis studies on rats after selective chemical denervation of the locus coeruleus projections: implications for the theory of depression
pp. S1/11-S1/11(1)
Authors: Harro J.; Kask A.; Pahkla R.; Rago L.; Tuomainen P.; Mannisto P.T.; Oreland L.

Effects of electroconvulsive seizures on protein kinase C-induced potentiation of cyclic AMP response are modified by pretreatment with antidepressant drugs
pp. S1/11-S1/11(1)
Authors: Nalepa I.; Kowalska M.; Vetulani J.

Pramipexole, a selective dopamine receptor agonist with potential antidepressant activity
pp. S1/11-S1/12(1)
Authors: Maj J.; Rogoz Z.; Skuza G.

Behavioral effects of acute and chronic Moclobemide administrations in mice
pp. S1/12-S1/12(1)
Authors: Akarsu E.S.; Palaoglu O.; Ayhan I.H.

Milnacipran, a new well-balanced double noradrenaline and serotonin reuptake inhibitor: Biochemical and pharmacological characteristics.
pp. S1/12-S1/12(1)
Authors: Briley M.; Moret C.

Depression and schizophrenia: brain stem auditory evoked potentials
pp. S1/13-S1/13(1)
Authors: Kimhi R.; Barak Y.; Levy D.; Zohar M.; Achiron A.; Elizur A.

Affective disorders are accompanied by cerebral asymmetry changes
pp. S1/13-S1/13(1)
Authors: Egorov A.Y.; Nikolaenko N.N.; Sechenov I.M.

Observations on depression during adolescence
pp. S1/13-S1/13(1)
Authors: Berti A.; Mungo S.

Variations in lymphocyte subsets in major depressive disorder
pp. S1/13-S1/13(1)
Authors: Ozcan E.; Eryilmaz M.M.; Karaman T.; Buyukberker C.; Birsoz S.; Undar L.

Blunted thyroid stimulating hormone and unaltered growth hormone responses to thyrothropine releasing hormone in major depression
pp. S1/14-S1/14(1)
Authors: Eryilmaz M.M.; Ozcan E.; Karaman T.; Birsoz S.; Buyukberker C.; Boz A.

Minimal electrocardiographic anomalies in patients treated with tricyclic antidepressants
pp. S1/14-S1/14(1)
Authors: Mungo S.; Muscella A.; Brizi C.; Mollica M.

Effects of Lithium treatment on thyroid functions in remitted bipolar patients
pp. S1/14-S1/14(1)
Authors: Gonul A.S.; Tutus A.; Sofuoglu S.; Esel E.; Kose K.; Aslan S.S.; Bastunrk M.

Cholesterol and suicidality in major depression: a pilot study
pp. S1/14-S1/15(1)
Authors: Dannon P.N.; Iancu I.; Hirschmann S.; Grunhaus L.; Zohar J.

Early P300 and late P300 in 415 treated patients suffering from a depressive syndrome
pp. S1/15-S1/15(1)
Authors: Debatisse D.; Lesnicki N.; Witdoeckt C.; Bolyn S.; Hansen I.; Maassen D.; Rakett D.; Pirotte B.; Joset M.; Castermans M.; Dewispelaere F.; Guerit J.M.; Hotermans J.M.; Bartholome F.; Kruger M.; Desfontaines P.; Troisfontaines P.; Boxus A.

Ambulatory eeg and sleep study in 194 treated depressed patients
pp. S1/15-S1/15(1)
Authors: Lesnicki N.; Boxus A.; Witdoeckt C.; Bolyn S.; Hansen I.; Massen D.; Raket D.; Pirotte B.; Joset M.; Castermans M.; Dewispelaere F.; Guerit J.M.; Hotermans J.M.; Bartholome F.; Kruger J.M.; Desfontaines P.; Troisfontaines P.; Debatisse D.

Depression and altered immunity: clinical implications for immunologic processes
pp. S1/15-S1/15(1)
Authors: Stankovska G.; Kirovski P.

The effects of interaction between the cholinergic and serotonergic systems on the cognitive impairment in depression and ECT
pp. S1/15-S1/16(1)
Authors: Levkovitz Y.; Bloch Y.; Treves I.; Neuman M.

Pharmacokinetic markers of psychotropic drug response
pp. S1/16-S1/16(1)
Authors: Rozov A.K.; Gorkov V.A.

The drug effects pharmacokinetic determinants as a basis for optimal psychotropic drug dosage form prediction
pp. S1/16-S1/16(1)
Authors: Karamisheva E.I.; Krilov Y.F.; Gorkov V.A.

Lithium pharmacokinetics and treatment of mood disorders
pp. S1/16-S1/17(1)
Authors: Gorkov V.A.; Churilin Y.Y.

Augmentation of antidepressant response by lithium - changes in acute phase proteins
pp. S1/17-S1/17(1)
Authors: Sluzewska A.; Rybakowski J.K.; Sobieska M.

Nifedipine steady-state pharmacokinetics in prophylactic treatment of mood disorders
pp. S1/17-S1/17(1)
Authors: Rozova G.I.; Snedkova L.V.; Chumakova A.I.; Gorkov V.A.

Pharmacokinetic-pharmacadynamic relationship of milnacipran on platelet uptake model
pp. S1/17-S1/18(1)
Authors: Puozzoa C.; Lambe R.; Briley M.

Milnacipran: A double and well-balanced noradrenaline and serotonin reuptake inhibitor: Results of comparative clinical trials
pp. S1/18-S1/18(1)
Authors: Tournoux A.; Tonelli I.; Denicourt L.

Efficacy and safety of sertraline in major depression
pp. S1/18-S1/19(1)
Author: Cetin M.

The efficacy and safety of sertraline in major depression
pp. S1/19-S1/19(1)
Authors: Gulseren S.; Aydemir O.; Kuey L.; Kultur S.

Moclobemide and sertraline in the treatment of melancholic depression: a comparative study
pp. S1/19-S1/19(1)
Authors: Iscan E.N.D.; Turkcapar M.H.; Orsel S.D.; Kilic E.O.; Sirin A.; Akdemir A.; Ozbay M.H.

Comparison of moclobemide and sertraline in the treatment of atypical depression: A preliminary study
pp. S1/19-S1/20(1)
Authors: Orsel S.D.; Turkcapar M.H.; Iscan E.N.D.; Akdemir A.; Sirin A.; Goka E.; Ozbay M.H.

Fluoxetine versus moclobemide in elderly depressed patients
pp. S1/20-S1/20(1)
Authors: Bugarski-Kirola D.; Zivkovic D.; Stankovic Z.; Damjanovic A.

Clopixol Acuphase(R) in the treatment of mania in a hospital setting
pp. S1/20-S1/20(1)
Authors: Stefanov S.; Hranov L.; Yanakiev N.; Dimitrova E.

Four-year outcomes for maintenance therapies in unipolar subjects with high probability of recurrence
pp. S1/20-S1/21(1)
Authors: Zanardi R.; Franchini L.; Gasperini M.; Perez J.; Smeraldi E.

The safeness of labetalol in electroconvulsive therapy
pp. S1/21-S1/21(1)
Authors: Dannon P.N.; Ross P.; Hirscmann S.; Iancu I.; Grunhaus L.

Can antidepressants prevent institutional care? Citalopram in the treatment of elderly depressed patients with and without dementia disorders
pp. S1/21-S1/22(1)
Authors: Koskinen T.; Lehto H.

Memory improving activity of fluoxetine in humans and rats
pp. S1/22-S1/22(1)
Authors: Nowakowska E.; Chodera A.; Kus K.; Rybakowski J.; Fellmann B.

The efficacy of cisapride in managing nausea produced by selective serotonin reuptake inhibitors: a placebo controlled study
pp. S1/22-S1/22(1)
Authors: Kara H.; Agargun M.Y.; Algun E.; Turkdogan M.K.; Tuncer I.

Antidepressant choice in the outpatient department of a psychiatry clinic
pp. S1/22-S1/22(1)
Authors: Icelli I.; Ozmen E.

Therapeutic consequences of inpatients' comorbidity and multimorbidity
pp. S1/23-S1/23(1)
Author: Molnar G.

Psychopharmacotherapy of comorbid mood disorders and pain syndromes
pp. S1/23-S1/23(1)
Authors: Doksat M.K.; Karaca E.; Kocak P.; Bayar M.R.

Training course for primary care physicians and medical students in the management of depression
pp. S1/23-S1/24(1)
Authors: Alkin T.; Tunca Z.; Yemez B.; Gogus A.

Antipanic properties of the selective 5HT_2C receptor agonist Ro 60-0332 and partial agonist Ro 60-0017 in a novel model of panic-like anxiety in rats
pp. S1/24-S1/24(1)
Authors: Jenck F.; Moreau J.-L.; Martin J.R.; Wichmann J.; Boes M.

Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors
pp. S1/24-S1/24(1)
Authors: Przegalinski E.; Tatarczynska E.; Deren-Wesolek A.; Chojnacka-Wojcik E.

The treatment of acute Posttraumatic Stress Disorder with Fluoxetine
pp. S1/24-S1/25(1)
Authors: Folnegovic-Smalcv V.; Folnegovic Z.; Kozaric-Kovacic D.; Makaric G.; Mimica N.

Reversible MAO-A inhibitors in the treatment of panic disorder
pp. S1/25-S1/25(1)
Authors: Georgiev S.; Hranov L.

A comparison fluvoxamine and cognitive-behaviour therapy in treatment of obsessive-compulsive disorder (OCD)
pp. S1/25-S1/25(1)
Author: Sungur M.Z.

Efficacy and safety of Paroxetine in Panic Disorder
pp. S1/25-S1/26(1)
Authors: Judge R.; Dunbar G.

Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: A double blind study
pp. S1/26-S1/26(1)
Authors: Burnham D.; Steiner M.; Gergel I.; Oakes R.; Bailer D.; Wheadon D.; Judge R.

The effects of amitriptyline and clomipramine on learning and memory in an elevated plus-maze test in mice
pp. S1/26-S1/26(1)
Authors: Nurten A.; Yamanturk P.; Enginar N.

The action of kavain, a kava pyrone prepared from the psychotropic remedy Piper methysticum, on presynaptic neurotransmission
pp. S1/26-S1/27(1)
Authors: Gleitz J.; Beile A.; Peters T.

Flumazenil exhibits a diazepam like-effect in Electroconvulsive shock-treated rats
pp. S1/27-S1/27(1)
Authors: Celik T.; Deniz G.; Ayhan I.H.

The effects of flumazenil on two-way active avoidance, in diazepam-treated rats
pp. S1/27-S1/27(1)
Authors: Celik T.; Deniz G.; Ayhan I.H.

Effects of L-Arginine on behavioural symptoms of ethanol withdrawal syndrome in rats
pp. S1/27-S1/28(1)
Authors: Uzbay I.T.; Erden B.F.; Sever B.

The importance of voltage-dependent calcium channel in withdrawal effects after chronic treatment with haloperidol
pp. S1/28-S1/28(1)
Authors: Michaluk J.T.; Vetulani J.; Karolewicz B.; Antkiewicz-Michaluk L.

Effects of acute administration of clozapine on local cerebral glucose utilization in the rat
pp. S1/28-S1/29(1)
Authors: Colangelo V.; Di Grezia R.; Orzi F.

L-NAME inhibits pentylenetetrazole and strychnine induced seizures in mice
pp. S1/29-S1/29(1)
Authors: Kaputlu I.; Uzbay I.T.

The effects of amlodipine and verapamil after peripheral and central administration against pentylenetetrazole convulsions
pp. S1/29-S1/29(1)
Authors: Dogrul A.; Uzbay I.T.; Deniz G.

The counteracting effects of bromocriptine on locomotor activity and its interaction with amlodipine
pp. S1/29-S1/30(1)
Authors: Dogrul A.; Uzbay I.T.; Deniz G.

Analgesic effects of intrathecal administration of calcium channel blockers in mice
pp. S1/30-S1/30(1)
Authors: Dogrul A.; Yesilyurt O.; Deniz G.

The analgesic effect of amlodipine and its interaction with morphine, ketorolac and naloxone after peripheral and central administration in mice
pp. S1/30-S1/30(1)
Authors: Dogrul A.; Deniz G.

Effects of dexfenfluramine on glucose-conditioned flavour preference in rats
pp. S1/30-S1/31(1)
Authors: Senoz S.; Yildiz O.; Deniz G.; Dogrul A.

Alteration of cholinergic pressor response in AF64A-induced Alzheimer model in rats
pp. S1/31-S1/31(1)
Authors: Tellioglu T.; Akin S.B.; Erin N.; Berkman K.; Oktay S.

Acetylcholine mediateds the effects of serotonin on hippocampal excitability in the intact rat brain
pp. S1/31-S1/32(1)
Authors: Levkovitz Y.; Segal M.

State of the mood and coping strategies in relation to the physical activity and fitness
pp. S1/32-S1/32(1)
Authors: Salloa M.; Rimm H.; Harro J.; Grauberg M.; Karelson K.; Viru A.

Glycine influence on white blood cells fermental status and psychological sights of teenagers with defiant behavior
pp. S1/32-S1/32(1)
Authors: Ternovskaya V.A.; Ternovsky L.N.; Zgontkova E.V.

Working out the system of health protection for persons of intellectual labor
pp. S1/32-S1/33(1)
Authors: Ternovskaya V.A.; Ternovsky L.N.; Uraloy A.V.

Platelets MAO in relation to alcohol abuse, suicidal or aggressive behavior among voluntarily admitted psychiatric patients
pp. S1/33-S1/33(1)
Authors: Wistedt B.; Gyllenhammar C.; Oreland L.; Palmstierna T.

Platelet guanine nucleotide-binding protein and antidepressant drugs treatment in major depressed patients
pp. S1/33-S1/34(1)
Authors: Karege F.; Stepanian R.; Schwald M.; Bovier P.

Search for possible molecular defects in the platelet serotonin (5-HT) carrier in patients with treatment-refractory endogenous depression
pp. S1/34-S1/34(1)
Authors: Lozier R.H.; Katasonov A.B.; Gratchev S.A.; Serebryadova M.V.; Pavlova O.A.; Brusov O.S.

The dexamethasone suppression test and thyroid releasing hormone test in major depression
pp. S1/34-S1/34(1)
Authors: Bilici M.; Taneli B.

Assistance of EEG in the diagnosis and treatment of anxiety disorders
pp. S1/34-S1/35(1)
Authors: Taneli B.; Taneli S.; Ozaskinli S.; Bas M.; Yilan U.; Bilici M.; Esen A.; Taneli T.